Intellia Therapeutics (NTLA) Misses Q2 EPS by 8c, beats revenue

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.40), $0.08 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $12.08 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• Aspire Biopharma to acquire automotive supplier for $30 million